Antihyperlipidaemics demonstrate long-term survival benefits

  • Published on

  • View

  • Download

Embed Size (px)


<ul><li><p>Inpharma 1605 - 15 Sep 2007</p><p>Antihyperlipidaemics demonstratelong-term survival benefits</p><p>Long-term follow-up data from the PRIME studyshowed reductions in all-cause mortality with lipid-lowering medications.</p><p>This prospective study involved 7855 men aged5060 years old who either received statin (HMG-CoAreductase inhibitor; n = 310) or fibric acid derivative(fibrates; 809) therapy, or received no such therapy andwere normolipidaemic (5340) or dyslipidaemic;*participants were followed up for 10 years.</p><p>Cox proportional hazards modelling showed that,compared with participants with untreateddyslipidaemia, participants who received statins orfibric acid derivatives had a significantly reduced all-cause mortality risk (HR 0.49; 95% CI 0.25, 0.93 and0.65; 0.43, 0.99, respectively) and a reducedcardiovascular mortality risk (0.46; 0.13, 1.54 and 0.65;0.31, 1.36). Corresponding values for untreatednormolipidaemic patients were 0.76; 0.56, 1.02 and0.38; 0.21, 0.61, respectively.</p><p>Moreover, cancer mortality risk was also decreasedamong statin and fibric acid derivative recipients, anduntreated normolipidaemic participants, compared withuntreated dyslipidaemic participants (0.39; 0.15, 1.01,0.51; 0.27, 0.96 and 0.70; 0.45, 1.07).</p><p>There were no significant differences between groupsin terms of mortality due to other causes.* defined as having a total cholesterol level of 250 mg/dL or atriglyceride level of 300 mg/dL</p><p>Gardette V, et al. Ten year all-cause mortality on lipid-lowering drugs ESCCongress 2007: Annual Congress of the European Society of Cardiology : 1 Sep2007 801035823</p><p>1</p><p>Inpharma 15 Sep 2007 No. 16051173-8324/10/1605-0001/$14.95 Adis 2010 Springer International Publishing AG. All rights reserved</p></li></ul>